– USA, CA – BioCardia®, Inc. (NASDAQ: BCDA) a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of Dr. Krisztina Zsebo, Ph.D. to its Board of Directors, following her election at the 2020 Annual Meeting of Stockholders in December 2020.
“Krisztina’s extensive experience in the industry, ranging from development to operations to commercialization, provides BioCardia with a significant resource as we continue our product development plans. We look forward to the benefit of her contributions to the Board and her unique perspective at this critical juncture,” said Dr. Peter Altman. “We also wish to thank both Fernando and Richard for their dedication and service to BioCardia’s board and wish them all the best in their future endeavors.”
Among her roles on the BioCardia Board of Directors, Dr. Zsebo is expected to serve as Chair of a Science and Technology Committee, with Dr. Simon Stertzer. She replaces Fernando Fernandez, whose term on the Board of Directors expired at the 2020 Annual Meeting of Stockholders in December.
Also, Richard Pfenniger, Jr. stepped down from Board in January 2021.
About Dr. Krisztina Zsebo
Dr. Zsebo has extensive biotechnology experience in discovery, development, and commercialization, having raised more than $200 million to support operations and having launched breakthrough technologies and products with total annual sales exceeding $3.5 billion. She was an integral member of the Amgen team that first cloned the molecule that would become Neupogen; identified the molecule and led the Amgen research team that developed Stemgen; and led Xenotech, a division of Cell Genysis, which developed Vectibix, a fully human antibody technology for colorectal cancer. In addition to her leadership and development experience, Dr. Zsebo has contributed to 113 biotechnology publications, has been awarded 34 composition, process, and method patents, and has 26 patents pending.
She earned her Ph.D. in biochemistry from the University of California, Berkeley.
BioCardia, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor-Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company’s products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.
For more information, visit www.BioCardia.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.